

Coloplast Annual General Meeting

2023/24



Mike | user of ostomy products

Chairman of the Board

Lars Rasmussen

Board of Directors

Other shareholder-elected Board members



Annette Brüs



Carsten Hellmann



Jette Nygaard-Andersen



Marianne Wiinholt

Board of Directors

Employee-elected Board members



Thomas Barfod



Roland Vendelbo Pedersen



Nikolaj Kyhe Gundersen

Executive Leadership Team



Kristian Villumsen
President & CEO



Anders Lonning-Skovgaard
Executive Vice President
& CFO



Caroline Vagner Rosenstand
Executive Vice President,
Voice & Respiratory Care



Allan Rasmussen
Executive Vice President,
Global Operations



Dorthe Rønnau
Executive Vice President,
People & Culture



Nicolai Buhl Andersen
Executive Vice President,
Chronic Care



Tommy Johns Jr
Executive Vice President,
Interventional Urology

Coloplast Annual General Meeting

2023/24



Torben | catheter user

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

- 1. Report by the Board of Directors**
- 2. Presentation and approval of the Annual Report**
- 3. Resolution on the distribution of profit**
- 4. Presentation and approval of the Remuneration Report**
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Chairman of the Board

Lars Rasmussen

Solidt annual result

8%

Organic growth

27%*

EBIT margin

*before special items



This year, Coloplast helped more than
2,000,000 people with intimate healthcare needs



Jason | catheter user

Executive Leadership Team



Kristian Villumsen
President & CEO



Anders Lonning-Skovgaard
Executive Vice President
& CFO



Caroline Vagner Rosenstand
Executive Vice President,
Voice & Respiratory Care



Allan Rasmussen
Executive Vice President,
Global Operations



Dorthe Rønnau
Executive Vice President,
People & Culture



Nicolai Buhl Andersen
Executive Vice President,
Chronic Care



Tommy Johns Jr
Executive Vice President,
Interventional Urology

Strive25 – focus on innovation and growth



Growth platform #1

Chronic Care

Ostomy care market

23-24 bn DKK
Global market size

4-5%
Market growth annually

35-40%
Market share globally

#1
Market position globally

Continence care market

18-19 bn DKK
Global market size

5-6%
Market growth annually

40-45%
Market share globally

#1
Market position globally

Lucie | uses ostomy products

Growth platform #2

Voice & Respiratory Care

Market for laryngectomy

1.5-2.0 bn DKK

Global market size

8-10%

Market growth annually

~85%

Market share globally

#1

Market position globally

Giorgio | uses Atos Medical products



Growth platform #3

Advanced Wound Care

Advanced wound care
market*

44-48 bn DKK
Globl market size

5-10%
Market share globally

Wound dressings / Biologics

2-4% / 6-8%
Market growth annually

#5
Market position globally

*Market size for Advanced dressings and Biologics

Abdallah | wound patient

Growth platform #4

Interventional Urology

Urology market

18-20 bn DKK
Market size globally

4-6%
Market growth annually

~15%
Global market share

#4
Market position globally

Colin | has a penile implant

Strive25 – Unparalleled efficiency



Strive25 – Sustainability



Strive25 – Leadership, culture & organisation



Key ratios 2023/24

mDKK	2023/24	2022/23	Change
Net revenue	27,030	24,500	10%
Gross margin	68%	67%	1% pp
Operating profit (EBIT)	7,286*	6,845*	6%
Operating margin (EBIT margin)	27%*	28%*	-1 pp
ROIC after tax	15%*	17%*	-2% pp

*Before special items

Profit 2023/24

Net profit for the year	DKK 5,052m
Total assets	DKK 48,073m
Equity	DKK 17,942m
Free cash flow for the year	DKK 1,430m
Net interest-bearing debt*	DKK 21,841m
Dividend DKK 22.00 per share	DKK 4,956m
Pay-out ratio	98%

* Includes an extraordinary tax payment of DKK 2.5 billion due to the transferring of IP rights related to the Atos Medical acquisition



Share price development



Outlook and guidance for 2024/25

8-9%

Organic growth

~28%*

Reported
EBIT margin

*Before special items

[Show Pete Reed film]

Coloplast Annual General Meeting

2023/24



Torben | catheter user

Agenda

- 1. Report by the Board of Directors**
- 2. Presentation and approval of the Annual Report**
- 3. Resolution on the distribution of profit**
- 4. Presentation and approval of the Remuneration Report**
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
- 5. Approval of the remuneration of the Board of Directors**
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

5. Approval of the remuneration of the Board of Directors

The Board of Directors proposes that the remuneration for the Board of Directors for the financial year 2024/25 be set as follows:

- Ordinary members of the Board are to receive a base fee of DKK 500,000.
- The Vice Chair is to receive a fee of DKK 875,000, equivalent to 1.75 times the base fee.
- The Chair is to receive a fee of DKK 1,500,000, equivalent to 3 times the base fee.

The Board further proposes that the remuneration for the financial year 2024/25 for ordinary members of the Audit Committee be set at DKK 300,000, and the remuneration for the Chair of the Audit Committee be set at DKK 500,000.

Additionally, the Board proposes that the remuneration for the financial year 2024/25 for ordinary members of the Remuneration and Nomination Committee be set at DKK 200,000, and the remuneration for the Chair of the Remuneration and Nomination Committee be set at DKK 300,000.

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
- 6. Proposals from the Board of Directors**
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
- 7. Election of members to the Board of Directors**
8. Election of auditors
9. Authorisation to the chairman of the meeting
10. Any other business

7. Election of members to the Board of Directors

The following members of the Board of Directors are proposed for re-election:

- Lars Rasmussen
- Niels Peter Louis-Hansen
- Annette Brüls
- Carsten Hellmann
- Jette Nygaard-Andersen
- Marianne Wiinholt

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
- 8. Election of auditors**
9. Authorisation to the chairman of the meeting
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
- 9. Authorisation to the chairman of the meeting**
10. Any other business

Agenda

1. Report by the Board of Directors
2. Presentation and approval of the Annual Report
3. Resolution on the distribution of profit
4. Presentation and approval of the Remuneration Report
5. Approval of the remuneration of the Board of Directors
6. Proposals from the Board of Directors
7. Election of members to the Board of Directors
8. Election of auditors
9. Authorisation to the chairman of the meeting
- 10. Any other business**



Coloplast